Allarity Therapeutics (ALLR) Non Operating Investment Income (2020 - 2022)
Allarity Therapeutics' (ALLR) quarterly Non Operating Investment Income came in at -$45000.0 in Q3 2022, up 67.15% YoY from -$26921.4 in Q3 2021, and down 32.35% on a QoQ basis from -$34000.0 in Q2 2022.
Allarity Therapeutics (ALLR) Non Operating Investment Income (2020 - 2022) Analysis & Trends
Allarity Therapeutics (ALLR) has 3 years of Non Operating Investment Income data on file, last reported at -$45000.0 in Q3 2022.
- Quarterly Non Operating Investment Income rose 67.15% year-over-year to -$45000.0 in Q3 2022, while the trailing twelve-month figure through Dec 2022 was -$115000.0 (up 76.77% YoY) and the FY2022 annual result came in at -$115000.0, up 76.77% from the prior year.
- Non Operating Investment Income retreated to -$45000.0 in Q3 2022, from -$34000.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $243000.0 in Q3 2020 to a low of -$178000.0 in Q4 2021.
- A 3-year average of -$34777.8 and a median of -$45000.0 in 2022 frame the typical range for Non Operating Investment Income.
- Annual changes were most pronounced in 2021 — Non Operating Investment Income plunged 429.63% — and 2022, when it surged 68.14%.
- Tracing ALLR's Non Operating Investment Income over 3 years: stood at $54000.0 in 2020, then sank by 429.63% to -$178000.0 in 2021, then soared by 74.72% to -$45000.0 in 2022.
- The last three Non Operating Investment Income figures came in at -$45000.0 (Q3 2022), -$34000.0 (Q2 2022), and -$36000.0 (Q1 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Allarity Therapeutics | 22.75 Mn | 22.75 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -45,000.00 |
| Sep 30, 2022 | -45,000.00 |
| Jun 30, 2022 | -34,000.00 |
| Jun 30, 2022 | -34,000.00 |
| Mar 31, 2022 | -36,000.00 |
| Mar 31, 2022 | -36,000.00 |
| Dec 31, 2021 | -178,000.00 |
| Dec 31, 2021 | -178,000.00 |
| Sep 30, 2021 | -137,000.00 |
| Sep 30, 2021 | -137,000.00 |
| Jun 30, 2021 | -67,000.00 |
| Jun 30, 2021 | -67,000.00 |
| Mar 31, 2021 | -113,000.00 |
| Mar 31, 2021 | -113,000.00 |
| Dec 31, 2020 | 54,000.00 |
| Dec 31, 2020 | 54,000.00 |
| Sep 30, 2020 | 243,000.00 |
| Sep 30, 2020 | 243,000.00 |